Ultragenyx Pharmaceutical
RARE
14.89
+0.43
+2.97%
Ultragenyx Pharmaceutical
US · RARE
#3012 by market cap
Listed 1970
14.89
+0.43
+2.97%
Live - 5344 symbols - heartbeat 329s ago
· 2026-10-08 07:00
Pre-market
14.85
-0.27%
After-hours
14.85
-0.27%
Overnight
14.89
0.00%
- Market cap
- 1.47B
- P/E (TTM)i
- -2.55
- P/Bi
- -5.04
- EPSi
- -5.83
- Div yieldi
- 0.00%
- 52W posi
- 8%
Reader sentiment
Are you bullish or bearish on RARE?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 19 analysts
Buy
Avg price target
32.06 +115.3%
Price target rangecurrent 14.89
Low18.00
Avg32.06
High68.00
Buy 58%
Hold 42%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-25 | H.C. Wainwright | -- | BUY | 25.00 |
| 2026-09-21 | Morgan Stanley | -- | HOLD | 20.00 |
| 2026-09-21 | Evercore | -- | HOLD | 18.00 |
| 2026-09-18 | CCORF | -- | BUY | 39.00 |
| 2026-09-18 | Wells Fargo | -- | HOLD | 18.00 |
| 2026-09-18 | William Blair | -- | HOLD | -- |
| 2026-09-18 | BofA Securities | -- | HOLD | 20.00 |
| 2026-09-18 | Wedbush | -- | HOLD | 23.00 |
| 2026-09-18 | Morgan Stanley | -- | HOLD | 20.00 |
| 2026-09-18 | Citi | -- | BUY | 32.00 |
| 2026-09-18 | Leerink Partners | -- | BUY | 33.00 |
| 2026-09-18 | Barclays | -- | BUY | 35.00 |
| 2026-09-17 | Cantor Fitzgerald | -- | BUY | 39.00 |
| 2026-09-05 | William Blair | -- | HOLD | -- |
| 2026-09-04 | Goldman Sachs | -- | HOLD | 19.00 |
| 2026-09-03 | Cantor Fitzgerald | -- | BUY | 33.00 |
| 2026-09-03 | CCORF | -- | BUY | 37.00 |
| 2026-09-03 | William Blair | -- | HOLD | -- |
| 2026-09-03 | Jefferies | -- | BUY | 28.00 |
| 2026-09-03 | Citi | -- | BUY | 28.00 |
| 2026-09-03 | Leerink Partners | -- | BUY | 33.00 |
| 2026-09-03 | Barclays | -- | BUY | 32.00 |
| 2026-09-03 | J.P. Morgan | -- | HOLD | 36.00 |
| 2026-09-02 | Cantor Fitzgerald | -- | BUY | 33.00 |
| 2026-09-02 | William Blair | -- | HOLD | -- |
Quant vs Street three independent views, side by side
Momentum strategy signal
Strong Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Deteriorating
7
■ Upgrades■ Downgrades
- 0 upgrades vs 7 downgrades among tracked analyst rating changes.
- Most recent: Evercore moved from Buy to Hold on 2026-09-21.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-09-21 | Evercore | BUY → HOLD | 18.00 |
| 2026-09-18 | BofA Securities | BUY → HOLD | 20.00 |
| 2026-09-18 | Morgan Stanley | BUY → HOLD | 20.00 |
| 2026-09-18 | Wells Fargo | BUY → HOLD | 18.00 |
| 2026-09-03 | J.P. Morgan | BUY → HOLD | 36.00 |
| 2026-09-02 | William Blair | BUY → HOLD | -- |
| 2026-03-24 | Goldman Sachs | BUY → HOLD | 25.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-04 | After close | ±19.62% | -3.41% (in line) |
| 2026/Q1 | 2026-05-05 | After close | ±8.84% | +3.68% (in line) |
| 2025/Q4 | 2026-02-12 | After close | ±8.40% | -12.68% (beat) |
| 2025/Q3 | 2025-11-04 | After close | ±11.35% | -1.82% (in line) |
| 2025/Q2 | 2025-08-05 | After close | ±9.32% | -3.01% (in line) |
| 2025/Q1 | 2025-05-06 | After close | ±18.50% | -4.68% (in line) |
| 2024/Q4 | 2025-02-13 | After close | ±13.82% | -2.37% (in line) |
| 2024/Q3 | 2024-11-05 | After close | ±13.99% | -3.18% (in line) |
| 2024/Q2 | 2024-08-01 | After close | ±11.60% | +14.31% (beat) |
| 2024/Q1 | 2024-05-02 | After close | ±9.84% | -1.04% (in line) |
| 2023/Q4 | 2024-02-15 | After close | ±15.02% | +5.75% (in line) |
| 2023/Q3 | 2023-11-02 | After close | ±10.62% | +6.09% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:00:14 · For reference only, not investment advice and not tailored to your situation.